ATE240725T1 - Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten - Google Patents

Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten

Info

Publication number
ATE240725T1
ATE240725T1 AT96908071T AT96908071T ATE240725T1 AT E240725 T1 ATE240725 T1 AT E240725T1 AT 96908071 T AT96908071 T AT 96908071T AT 96908071 T AT96908071 T AT 96908071T AT E240725 T1 ATE240725 T1 AT E240725T1
Authority
AT
Austria
Prior art keywords
rar
agents
contain
treatment
light
Prior art date
Application number
AT96908071T
Other languages
English (en)
Inventor
Graeme Findlay Bryce
Stanley Seymour Shapiro
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE240725T1 publication Critical patent/ATE240725T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96908071T 1995-03-31 1996-03-19 Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten ATE240725T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/414,242 US5807900A (en) 1995-03-31 1995-03-31 Method for identifying compounds having increased activity for the repair of skin photodamage
PCT/EP1996/001176 WO1996030009A2 (en) 1995-03-31 1996-03-19 Compositions for treatment of photodamaged skin comprising an rar-alpha antagonist and a multi-selective retinoid

Publications (1)

Publication Number Publication Date
ATE240725T1 true ATE240725T1 (de) 2003-06-15

Family

ID=23640589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908071T ATE240725T1 (de) 1995-03-31 1996-03-19 Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten

Country Status (9)

Country Link
US (1) US5807900A (de)
EP (1) EP0817625B1 (de)
AT (1) ATE240725T1 (de)
AU (1) AU5146096A (de)
DE (1) DE69628287T2 (de)
DK (1) DK0817625T3 (de)
ES (1) ES2201175T3 (de)
PT (1) PT817625E (de)
WO (1) WO1996030009A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
FR2755011B1 (fr) * 1996-10-31 1998-11-20 Cird Galderma Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v.
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
CA2344696A1 (en) * 1998-10-14 2000-04-20 John J. Voorhees Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid
DE19926779A1 (de) * 1999-06-11 2000-12-14 Basf Ag Verwendung von substituierten Vinyl-tetrahydronaphthalinen und Vinyl-benzotetrahydropyranen als Lichtschutzmittel
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of emphysema using rar selective retinoid antagonists
KR100582806B1 (ko) 2000-05-02 2006-05-23 에프. 호프만-라 로슈 아게 신규한 감마 선택적인 레티노이드
EP1935869A1 (de) 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoide zur Behandlung von Emphysem
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
WO2012076842A1 (en) * 2010-12-09 2012-06-14 University Of Durham Synthetic retinoids for control of cell differentiation
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
EP2969031A4 (de) * 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topische zusammensetzungen zur reduzierung von alterungserscheinungen
ES3070746T3 (es) 2019-10-02 2026-06-17 Inst Nat Sante Rech Med Agonistas del receptor del ácido retinoico (RAR) para revertir, prevenir o retrasar la calcificación de la válvula aórtica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
WO1988007857A1 (en) * 1987-04-06 1988-10-20 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US5075333A (en) * 1987-08-19 1991-12-24 Hoffmann-La Roche Inc. Tetrahydronaphthalene and indane compounds useful for reversing the photo-damage in sun-exposed skin
DE69232188T2 (de) * 1991-08-23 2002-06-20 Ligand Pharmaceuticals, Inc. Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen
CZ282548B6 (cs) * 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
CA2093577C (en) * 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids

Also Published As

Publication number Publication date
WO1996030009A2 (en) 1996-10-03
AU5146096A (en) 1996-10-16
PT817625E (pt) 2003-10-31
DK0817625T3 (da) 2003-09-15
DE69628287D1 (de) 2003-06-26
DE69628287T2 (de) 2004-04-08
WO1996030009A3 (en) 1997-01-03
EP0817625B1 (de) 2003-05-21
US5807900A (en) 1998-09-15
EP0817625A2 (de) 1998-01-14
ES2201175T3 (es) 2004-03-16

Similar Documents

Publication Publication Date Title
DE69628287D1 (de) Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
DE69512685D1 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
FI973468L (fi) Hampaiden valkaisemiseen tai ihon ja limakalvojen sairauksien hoitoon käytettävien valmisteiden valmistusmenetelmä
ATE181824T1 (de) Mittel zur feuchthaltung von gewebe und verfahren
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
ES2164916T3 (es) Tratamiento de la esclerosis multiple.
BR9611137A (pt) Composições e métodos para distribuição bucal de agentes farmacêuticos
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
IL122405A (en) Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
ATE192731T1 (de) Retinoid trienverbindungen und verfahren
EP0767666A4 (de) Verfahren und präparate für die prophylaxe und therapie von mit endotoxin verbundenen zuständen
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
ATE289808T1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
AR004052A1 (es) Una composición cosmética o farmacéutica que comprende un agonista beta-adrenergico
ZA984268B (en) Method and composition for administering taxanes orally to human patients
BR0317805A (pt) Composição de cuidados oral ou pessoal, processo para produzir uma composição de cuidado oral, e, composição para aumentar a saúde, higiene ou aparência pessoais
GB9400691D0 (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
DE69519933D1 (de) Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0817625

Country of ref document: EP